| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 0 | 0 | 0 | 0 | 0 | 1.217 | - | - |
| Total Income - EUR | - | - | 0 | 0 | 0 | 0 | 40.259 | 1.217 | - | - |
| Total Expenses - EUR | - | - | 623 | -455 | 1.771 | 17.016 | 27.595 | 30.964 | - | - |
| Gross Profit/Loss - EUR | - | - | -623 | 455 | -1.771 | -17.016 | 12.664 | -29.747 | - | - |
| Net Profit/Loss - EUR | - | - | -623 | 455 | -1.771 | -17.017 | 12.658 | -29.759 | - | - |
| Employees | - | - | 0 | 0 | 0 | 4 | 4 | 4 | - | - |
Check the financial reports for the company - Vademecum Building Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 77 | 0 | 33.956 | 31.170 | 26.505 | 24.097 | - | - |
| Current Assets | - | - | 109 | 638 | 14 | 68 | 332 | 2.760 | - | - |
| Inventories | - | - | 0 | 0 | 0 | 0 | 0 | 2.223 | - | - |
| Receivables | - | - | 0 | 0 | 0 | 0 | 0 | 507 | - | - |
| Cash | - | - | 109 | 638 | 14 | 68 | 332 | 29 | - | - |
| Shareholders Funds | - | - | -580 | -114 | -1.883 | -18.865 | -5.789 | -35.566 | - | - |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | - | - |
| Debts | - | - | 766 | 752 | 35.853 | 50.102 | 32.626 | 62.422 | - | - |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4120 - 4120" | |||||||||
| CAEN Financial Year |
4120
|
|||||||||
Comments - Vademecum Building Srl